Prosperity Wealth Management Inc. Takes $300,000 Position in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Prosperity Wealth Management Inc. acquired a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,300 shares of the company's stock, valued at approximately $300,000.

A number of other hedge funds have also made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after purchasing an additional 150 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in BioNTech in the 4th quarter valued at $1,118,000. Charles Schwab Investment Management Inc. grew its stake in BioNTech by 39.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock valued at $21,349,000 after buying an additional 53,319 shares during the last quarter. Raymond James Financial Inc. acquired a new position in BioNTech in the 4th quarter valued at $584,000. Finally, Flossbach Von Storch SE grew its stake in BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock valued at $502,160,000 after buying an additional 47,236 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Price Performance

Shares of BioNTech stock traded up $2.13 during trading on Friday, hitting $106.53. 721,507 shares of the company's stock traded hands, compared to its average volume of 950,228. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The firm's fifty day moving average price is $102.22 and its 200 day moving average price is $107.64. The company has a market cap of $25.61 billion, a PE ratio of -31.33 and a beta of 1.29. BioNTech SE Sponsored ADR has a twelve month low of $76.53 and a twelve month high of $131.49.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on BNTX shares. Morgan Stanley lowered their price target on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. BMO Capital Markets raised their target price on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. The Goldman Sachs Group assumed coverage on BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 target price on the stock. Finally, HC Wainwright lowered their price objective on shares of BioNTech from $145.00 to $138.00 and set a "buy" rating on the stock in a research note on Monday, June 16th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $137.86.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.